Corient IA LLC Purchases New Position in Danaher Corporation $DHR

Key Points

• Corient IA LLC has acquired a new stake in Danaher Corporation, purchasing 1,500 shares valued at approximately $308,000 in the first quarter.
• Recent institutional investment activity shows that 79.05% of Danaher’s stock is owned by institutional investors, highlighting strong interest from the market.
• Despite some analysts reducing target prices, Danaher holds a consensus rating of "Moderate Buy" with an average target price of $247.61.

Corient IA LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,500 shares of the conglomerate's stock, valued at approximately $308,000.

A number of other hedge funds have also made changes to their positions in DHR. Fayez Sarofim & Co lifted its stake in Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after buying an additional 50 shares during the last quarter. Coastal Bridge Advisors LLC increased its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares during the period. MGO One Seven LLC increased its holdings in shares of Danaher by 1.3% during the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock valued at $984,000 after purchasing an additional 53 shares during the period. Hills Bank & Trust Co increased its holdings in shares of Danaher by 0.3% during the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after purchasing an additional 53 shares during the period. Finally, Sageworth Trust Co increased its holdings in shares of Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Argus lowered their price target on Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. HSBC lowered their price target on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Robert W. Baird raised their price target on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Trading Down 3.4%

DHR traded down $7.2480 during trading on Thursday, reaching $204.1520. The company had a trading volume of 3,172,582 shares, compared to its average volume of 4,228,694. The firm's 50-day simple moving average is $200.46 and its 200 day simple moving average is $199.62. The company has a market cap of $146.18 billion, a price-to-earnings ratio of 43.44, a PEG ratio of 2.96 and a beta of 0.73. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the business posted $1.72 EPS. Danaher's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.